

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

204654Orig1s000

SUMMARY REVIEW

Cross-Discipline Team Leader Review

Date	July 24, 2013
From	Lisa M. Soule, M.D.
Subject	Cross-Discipline Team Leader Review
NDA/BLA #	204-654
Applicant	Warner Chilcott Company, LLC
Date of Submission	September 28, 2012
PDUFA Goal Date	July 28, 2013
Proprietary Name / Established (USAN) names	Lo Minastrin Fe Ethinyl estradiol (EE)/Norethindrone acetate (NETA), EE alone, and ferrous fumarate (FF) tablets
Dosage forms / Strength	EE 10 µg/NETA 1 mg chewable tablet and EE 10 µg tablet to be swallowed
Dose Regimen	1 EE/NETA chewable tablet daily for 24 days, followed by 2 days of EE-alone (swallowed) and 2 days of FF tablets (swallowed)
Proposed Indication(s)	Prevention of pregnancy
Recommended:	<i>Approval</i>

1. Introduction

This NDA seeks approval for a chewable combination oral contraceptive (COC) containing norethindrone acetate (NETA) and ethinyl estradiol (EE); the COC is intended to be bioequivalent (BE) to the COC Lo Loestrin Fe, approved under NDA 22-501. The dose regimen is the same as that for Lo Loestrin Fe aside from chewing the combination tablets, and consists of:

- Days 1-24: one mint-flavored combination EE/NETA tablet (chewed)
- Days 25-26: one 10 µg EE-alone tablet (swallowed)
- Days 27-28: one inactive tablet containing ferrous fumarate (FF, swallowed).

Tablets may be taken without regard to meals.

There are several approved NDAs for chewable COCs; those currently marketed are Femcon Fe (NDA 21-490) and Generess Fe (NDA 22-573).

2. Background

2.1 DESCRIPTION OF PRODUCT

NETA and EE are well-characterized progestin and estrogen products, respectively, that are widely used in combined hormonal contraceptive products. These products reduce the risk of pregnancy mainly via the effect of the progestin on suppressing ovulation, along with changes in cervical mucus that inhibit sperm motility and endometrial changes that may inhibit implantation. The estrogen component may make some contribution to the contraceptive action, and mainly acts to maintain cycle control and provide an acceptable bleeding profile.

The Applicant has several approved COC products that contain EE and NETA. The Loestrin family of products had its initial approval in 1976, and includes Loestrin products containing 30 µg EE/1.5 mg NETA or 20 µg EE/1 mg NETA administered in a 21/7 regimen; Loestrin 24 Fe, which contains 20 µg EE/1 mg NETA and is administered in a 24/4 day regimen with four days of FF, and Lo Loestrin Fe, which contains 10 µg EE/1 mg NETA and is administered in a 24/2/2 day regimen with two days of EE-alone and two days of FF. Lo Loestrin Fe contains the lowest EE dose in any approved COC, and is the reference drug for the current chewable tablet.

Of the chewable formulations (most manufactured by another sponsor), Femcon Fe was approved in 2003 and contains 35 µg EE/400 µg NETA administered in a regimen of 21 days of active combination tablets and 7 days of FF tablets. A lower dose version, Generess, was approved in 2010; it contains 25 µg EE/800 µg NETA, and is administered in the same regimen as Femcon Fe. Another Warner Chilcott chewable product, BE to Loestrin 24 Fe, was approved under NDA 203-667 in May 2013 and has not yet been marketed. A capsule bioequivalent to Loestrin 24 Fe was also approved, under NDA 204-426, in April 2013 and has not yet been marketed.

2.2 REGULATORY HISTORY

Because the Applicant had experience developing chewable formulations of approved COC products, it understood the Division's requirements for approval of such a formulation (e.g., conduct of an oral irritation study) and did not request advice during the development program for this product.

2.3 PRIMARY MEDICAL REVIEWER'S RECOMMENDATION FOR APPROVABILITY

The primary reviewer, Dr. Daniel Davis, stated in his review dated July 5, 2013:

From a clinical perspective, this reviewer recommends approval of NETA/EE chewable tablets containing norethindrone ACETATE (NETA) 1 mg and ethinyl estradiol (EE) 10 mcg for the Applicant's proposed indication of "for use by women to prevent pregnancy." The new product will be marketed as a 28-day regimen.

Team Leader Comment:

I concur with Dr. Davis' recommendation.

Dr. Davis did not recommend any postmarketing risk evaluation and mitigation strategies or postmarketing requirements/commitments.

3. CMC/Device

3.1 CMC

A USP monograph about the combination of the drug substances (EE and NETA) has been published. Information about each drug substance from its respective manufacturer is contained in drug master files (DMFs), which have been reviewed several times and determined to be adequate. The primary Chemistry Reviewer, Gene Holbert, Ph.D., noted that the formulation of the chewable combination tablets (b)(4) is based on the previously approved formulation in NDA 22-501, with the difference being that the current tablet is chewable. The formulations are identical except for (b)(4)

Dissolution

data confirm that the release of NETA and EE are similar for both formulations. The EE-alone and FF tablets are identical to those approved in NDA 22-501.

Dr. Holbert found the analytic methods to be appropriately validated. Expiry of 12 months was proposed by the Applicant based on six month data for the combination tablets at the long-term and intermediate conditions and extrapolation of the long-term data; this was acceptable. The expiry will be amended as results of ongoing stability testing become available.

Dr. Holbert provided labeling recommendations that were conveyed to the Applicant; carton and container labeling were acceptable. Five manufacturing and testing sites were found acceptable on profile and one based on district recommendation. One drug substance manufacturer ^{(b) (4)} was scheduled for inspection and one had been inspected but no recommendation made at the time of his review.

At the time of Dr. Holbert's review, labeling negotiations had not been completed and the overall recommendation by the Office of Compliance was pending; therefore, he made the following recommendations in his review dated June 18, 2013:

The applicant has provided sufficient information to assure the identity, strength, purity, and quality of the drug product.

*The Office of Compliance has **not** issued made an overall "Acceptable" recommendation for the facilities involved in the NDA as of the date of this review.*

*Labels/labeling issues have **not** yet been resolved.*

*Therefore, from the ONDQA perspective, this NDA is **not** recommended for approval per 21 CFR 314.125(b)(1), (13) until the issues delineated above are satisfactorily resolved.*

No post-marketing commitments or risk management strategies were recommended.

Following submission of acceptable labeling, Dr. Holbert submitted an addendum to his review on July 23, 2013, noting that CMC-related labeling issues had been resolved and carton/container labeling was acceptable. The Office of Compliance issues an overall "Acceptable" recommendation on July 9, 2013. He made the following recommendation:

*This NDA is now recommended for **Approval** from the ONDQA perspective with an expiration dating period of 12 months.*

4. Nonclinical Pharmacology/Toxicology

The Applicant did not conduct any preclinical studies for this NDA, but referenced the NDA for its existing Lo Loestrin Fe product (22-501) to fulfill the requirements for nonclinical evaluation. The active ingredients are the same as those in the NDA 22-501, while the inactive ingredients are either compendial or Generally Recognized as Safe and are at or below the quantities listed in the FDA Inactive Ingredient Database for a chewable or oral tablet.

The primary Toxicology Reviewer, Krishan Raheja, D.V.M., Ph.D., made the following recommendations in his NDA review dated April 19, 2013:

Recommendations on approvability: Pharmacology/Toxicology recommends approved of (b) (4) under NDA 204654 for the indication of prevention of pregnancy.

Additional Non Clinical Recommendations: None

Recommendations on labeling: Sponsor has provided drug label in PLR format which is acceptable from the Pharmacology/Toxicology perspective.

5. Clinical Pharmacology/Pharmacometrics

5.1 Clinical Pharmacology

The Applicant submitted a bioequivalence (BE) study, Study PR-12111 to demonstrate that the chewable combination tablets in this NDA (known as (b) (4) 1/10 tablets) are bioequivalent to the combination tablets taken by swallowing with water in the approved product Lo Loestrin Fe. The EE-alone and FF tablets are identical to those used in Lo Loestrin so no demonstration of bioequivalence was needed for those tablets. Study PR-12111 also evaluated the effect of food on the bioavailability of NETA and EE from the (b) (4) 1/10 tablets.

The primary Clinical Pharmacology Reviewer, Li Li, Ph.D., concluded that the NETA and EE exposure with (b) (4) 1/10 tablets was bioequivalent to that obtained with the combination tablets from Lo Loestrin Fe. The 90% confidence intervals for the test:reference ratio for C_{max}, AUC_{0-t} and AUC_{0-inf} were within the 80-125% limit for both NETA and EE when both drugs were administered under fasting conditions. When the bioavailability of (b) (4) 1/10 tablets were compared for fasting and fed conditions (a high fat meal), the fed condition reduced the rate (T_{max}), but not the extent of NETA and EE absorption. However, (b) (4) 1/10 tablets administered under fed conditions remained bioequivalent to Lo Loestrin Fe tablets (fasting).

No new drug interaction studies were conducted, nor were studies done to evaluate the impact of renal or hepatic impairment. Information from Lo Loestrin Fe labeling will be provided in the labeling for this chewable product.

Dr. Li stated the following in her review dated June 20, 2013:

The Office of Clinical Pharmacology/Division of Clinical Pharmacology 3 (OCP/DCP3) finds NDA 204654 acceptable provided that agreement is reached between the Sponsor and the Division regarding the language in the package insert..

Dr. Li did not recommend any phase 4 requirements or commitments.

Following submission of acceptable labeling, Dr. Li submitted an addendum to her review on July 24, 2013, noting that labeling issues had been resolved and the final labeling was acceptable. She made the following recommendation:

The Division of Clinical Pharmacology-3, Office of Clinical Pharmacology finds the NDA 204654 acceptable .

6. Clinical Microbiology

No clinical microbiology consult was requested for this oral tablet product.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.